Author response: NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency

Marques, Joana G.; Gryder, Berkley E.; Pavlovic, Blaz; Chung, Yeonjoo; Ngo, Quy A.; Frommelt, Fabian; Gstaiger, Matthias; Song, Young K.; Benischke, Katharina; Laubscher, Dominik; Wachtel, Marco; Khan, Javed; Schäfer, Beat W.

doi:10.7554/elife.54993.sa2

2020

DOI: 10.7554/elife.54993.sa2

|View full text |Cite

Author response: NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency

Joana G. Marques

Berkley E. Gryder

Blaz Pavlovic

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma

Dreher

Theisen

2023

Front. Oncol.

View full text Add to dashboard Cite

Sarcomas are a diverse group of tumors with numerous oncogenic drivers, and display varied clinical behaviors and prognoses. This complexity makes diagnosis and the development of new and effective treatments challenging. An incomplete understanding of both cell of origin and the biological drivers of sarcomas complicates efforts to develop clinically relevant model systems and find new molecular targets. Notably, the histone lysine specific demethylase 1 (LSD1) is overexpressed in a number of different sarcomas and is a potential therapeutic target in these malignancies. With the ability to modify histone marks, LSD1 is a key player in many protein complexes that epigenetically regulate gene expression. It is a largely context dependent enzyme, having vastly different and often opposing roles depending on the cellular environment and which interaction partners are involved. LSD1 has been implicated in the development of many different types of cancer, but its role in bone and soft tissue sarcomas remains poorly understood. In this review, we compiled what is known about the LSD1 function in various sarcomas, to determine where knowledge is lacking and to find what theme emerge to characterize how LSD1 is a key molecular driver in bone and soft tissue sarcoma. We further discuss the current clinical landscape for the development of LSD1 inhibitors and where sarcomas have been included in early clinical trials.

show abstract

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma

Dreher

Theisen

2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Author response: NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency

Cited by 1 publication

References 0 publications

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma

Contact Info

Product

Resources

About